ImmunoGen Inc. (NASDAQ:IMGN) shares traded -16.00% lower at $14.33 on Wall Street last session.
In accordance with the data, 11 analysts cover ImmunoGen Inc. (NASDAQ:IMGN). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $26.00 and a low of $13.00, we find $24.00. Given the previous closing price of $17.06, this indicates a potential upside of 40.68 percent. IMGN stock price is now -18.89% away from the 50-day moving average and 66.64% away from the 200-day moving average. The market capitalization of the company currently stands at $3.47B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
It has been rated a hold by 1 analysts and a buy by 9. Brokers who have rated the stock have averaged $22.89 as their price target over the next twelve months.
With the price target enhanced from $6 to $16, Piper Sandler Upgraded its rating from Neutral to Overweight for ImmunoGen Inc. (NASDAQ: IMGN).
In other news, Enyedy Mark J, CHIEF EXECUTIVE OFFICER sold 992,397 shares of the company’s stock on Aug 04. The stock was sold for $16,831,053 at an average price of $16.96. Upon completion of the transaction, the CHIEF EXECUTIVE OFFICER now directly owns 553,270 shares in the company, valued at $7.93 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 04, SVP & CHIEF BUSINESS OFFICER Coen Stacy Ann sold 80,326 shares of the business’s stock. A total of $1,369,558 was realized by selling the stock at an average price of $17.05. This leaves the insider owning 10,960 shares of the company worth $0.16 million. A total of 0.30% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in IMGN stock. A new stake in ImmunoGen Inc. shares was purchased by ARTISAN PARTNERS LIMITED PARTNERSHIP during the first quarter worth $45,589,000. EMERALD ADVISERS, LLC invested $14,096,000 in shares of IMGN during the first quarter. In the first quarter, PROFUND ADVISORS LLC acquired a new stake in ImmunoGen Inc. valued at approximately $3,623,000. MAN GROUP PLC acquired a new stake in IMGN for approximately $3,092,000. MOODY ALDRICH PARTNERS LLC purchased a new stake in IMGN valued at around $2,936,000 in the second quarter.
ImmunoGen Inc. (NASDAQ: IMGN) opened at $16.80 on Monday. During the past 12 months, ImmunoGen Inc. has had a low of $3.61 and a high of $20.69. As of last week, the company has a debt-to-equity ratio of 0.15, a current ratio of 7.10, and a quick ratio of 7.10. The fifty day moving average price for IMGN is $17.68 and a two-hundred day moving average price translates $8.64 for the stock.
The latest earnings results from ImmunoGen Inc. (NASDAQ: IMGN) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.02, beating analysts’ expectations of -$0.14 by 0.12. This compares to -$0.24 EPS in the same period last year. The net profit margin was -96.00% and return on equity was -76.90% for IMGN. The company reported revenue of $83.15 million for the quarter, compared to $14.16 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 487.16 percent. For the current quarter, analysts expect IMGN to generate $99.53M in revenue.
ImmunoGen Inc.(IMGN) Company Profile
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
